Domzalski David 4
4 · VYNE Therapeutics Inc. · Filed Jun 4, 2024
Insider Transaction Report
Form 4
Domzalski David
DirectorPRESIDENT AND CEO
Transactions
- Award
Common Stock
2024-05-31$2.16/sh+4,429$9,562→ 498,589 total
Footnotes (1)
- [F1]These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2023 and ending on May 31, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on May 31, 2024.